6 .	Commitments and Contingencies

Leases

We lease

28,275

square feet of laboratory and office space in San Diego, California under a lease that began on

December 1, 2016

and expires on

April 15, 2024.

May 2018,

we entered into a lease amendment to expand our space in San Diego, adding an additional

23,873

square feet. The lease of the additional space began on

September 7, 2018

and expires on

December 31, 2025.

We have

one

-year option to renew this lease on expiration. We lease

26,067

square feet of laboratory, office and warehouse space in Redwood City, California. The lease for the Redwood City space expires on

May 31, 2019.

March 15, 2018,

we entered into a sublease agreement for the Redwood City property. The sublease agreement expires on

May 31, 2019.

We also lease

1,898

square feet of office space in Jersey City, New Jersey. The lease for the Jersey City office space expires on

June 30, 2019.

For the year ended

December 31, 2018,

rent expense for all properties was

$3.2

million. We believe our facilities are adequate and suitable for our current needs and that we will be able to obtain new or additional leased space in the future when necessary.

Annual future minimum lease payments as of

December

31,

2018

are as follows (in thousands):

Year ended December 31:
2019	$	3,195
2020		2,722
2021		2,801
2022		2,883
2023		2,967
Thereafter		3,274
Total future minimum lease payments	$	17,842

Rent expense under all operating leases totaled

$3.2

million,

$3.1

million and

$2.1

million for the years ended

December

31,

2018,

2017

and

2016,

respectively.

Clinical Development Agreements

We enter into agreements with clinical sites and clinical research organizations for the conduct of our clinical trials. We make payments to these sites and organizations based in part on the number of eligible patients enrolled and the length of their participation in the clinical trials. Under certain of these agreements, we

may

be subject to penalties in the event that we prematurely terminate these agreements. At this time, due to the variability associated with clinical site and contract research organization agreements, we are unable to estimate with certainty the future costs we will incur. We intend to use our current financial resources to fund our obligations under these commitments.